newsfilter
← Latest News
GlobeNewswire·

Otonomy Reports Corporate and Product Pipeline Update

Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biop